

Tomoyasu Fukui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6479684/publications.pdf>

Version: 2024-02-01

22
papers

195
citations

1039406

9
h-index

1125271

13
g-index

22
all docs

22
docs citations

22
times ranked

280
citing authors

#	ARTICLE	IF	CITATIONS
1	A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4811.	1.8	20
2	Type 1 diabetes patients have lower strength in femoral bone determined by quantitative computed tomography: A cross-sectional study. <i>Journal of Diabetes Investigation</i> , 2015, 6, 726-733.	1.1	19
3	Analysis of pancreatic volume in acute-onset, slowly-progressive and fulminant type 1 diabetes in a Japanese population. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1091-1099.	1.1	17
4	Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E895-E907.	1.8	17
5	Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. <i>Diabetes Therapy</i> , 2019, 10, 215-228.	1.2	16
6	AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9263.	1.8	11
7	Pancreatic ductal hyperplasia/dysplasia with obstructive chronic pancreatitis: an association with reduced pancreatic weight in type 1 diabetes. <i>Diabetologia</i> , 2016, 59, 865-867.	2.9	10
8	Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 339-346.	1.1	10
9	Quadrant Analysis of Quantitative Computed Tomography Scans of the Femoral Neck Reveals Superior Region-Specific Weakness in Young and Middle-Aged Men With Type 1 Diabetes Mellitus. <i>Journal of Clinical Densitometry</i> , 2018, 21, 172-178.	0.5	10
10	Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes. <i>Drugs in R and D</i> , 2015, 15, 245-251.	1.1	9
11	Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107904.	1.1	9
12	Luseogliflozin inhibits high glucose-induced TGF- β 2 expression in mouse cardiomyocytes by suppressing NHE-1 activity. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210974.	0.4	8
13	Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: A long-term follow-up study. <i>Endocrine Journal</i> , 2013, 60, 715-724.	0.7	7
14	Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway. <i>Biomedicines</i> , 2021, 9, 832.	1.4	7
15	Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1480-1489.	1.1	5
16	Anti-inflammatory and atheroprotective properties of glucagon. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412096518.	0.9	5
17	Pancreatic fat accumulation evaluated by multidetector computed tomography in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1188-1196.	1.1	4
18	Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF- β 2. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412199903.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3415.	1.7	3
20	Relationship Between Islet Autoantibodies and Pancreatic Volume in Type 1 Diabetes in Japanese Population. <i>Diabetes and Endocrinology</i> , 2019, 2, .	0.0	2
21	A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. <i>Diabetology International</i> , 2016, 7, 425-431.	0.7	1
22	Association between insulin-like growth factor 1 and pancreatic volume in type 1 and type 2 diabetes: cross-sectional study of a Japanese population. <i>Growth Hormone and IGF Research</i> , 2021, 59, 101396.	0.5	1